Orange Book product · Brand (NDA)
KISQALI
RIBOCICLIB SUCCINATE
At a glance
Mar 13, 2017
Approved
Brand (NDA)
Application
Not listed
TE code
43
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 13, 2017
9 yr 5 mo ago
Today
Exclusivity ends · I-950
New indication exclusivity (3 years)
Sep 17, 2027
in 1 yr 3 mo
Exclusivity ends · PED
Pediatric exclusivity (adds 6 months)
Mar 17, 2028
in 1 yr 9 mo
Patent 8324225 expires
Listed drug substance patent expiration.
Jun 17, 2028
in 2 yr
Patent 8324225*PED expires
Listed listed patent expiration.
Dec 17, 2028
in 2 yr 6 mo
Patent 9416136 expires
Listed method-of-use patent (U-2355) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-2356) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-1981) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-3999) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-3266) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-3265) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 9416136 expires
Listed method-of-use patent (U-3975) expiration.
Aug 20, 2029
in 3 yr 3 mo
Patent 8962630 expires
Listed method-of-use patent (U-1981) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-2356) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-2355) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-3999) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-3265) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-3266) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 8962630 expires
Listed method-of-use patent (U-3975) expiration.
Dec 09, 2029
in 3 yr 6 mo
Patent 9416136*PED expires
Listed listed patent expiration.
Feb 20, 2030
in 3 yr 9 mo
Patent 8685980 expires
Listed drug substance patent expiration.
May 25, 2030
in 4 yr
Patent 8962630*PED expires
Listed listed patent expiration.
Jun 09, 2030
in 4 yr
Patent 8685980*PED expires
Listed listed patent expiration.
Nov 25, 2030
in 4 yr 6 mo
Patent 8415355 expires
Listed drug substance patent expiration.
Mar 13, 2031
in 4 yr 10 mo
Patent 8415355*PED expires
Listed listed patent expiration.
Sep 13, 2031
in 5 yr 4 mo
Patent 9193732 expires
Listed drug substance patent expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-2355) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-2356) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-3999) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-1981) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-3975) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-3265) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9868739 expires
Listed method-of-use patent (U-3266) expiration.
Nov 09, 2031
in 5 yr 6 mo
Patent 9193732*PED expires
Listed listed patent expiration.
May 09, 2032
in 6 yr
Patent 9868739*PED expires
Listed listed patent expiration.
May 09, 2032
in 6 yr
Patent 12544379 expires
Listed method-of-use patent (U-3975) expiration.
Aug 07, 2034
in 8 yr 3 mo
Patent 12544380 expires
Listed method-of-use patent (U-4404) expiration.
Aug 07, 2034
in 8 yr 3 mo
Patent 12544380 expires
Listed method-of-use patent (U-4405) expiration.
Aug 07, 2034
in 8 yr 3 mo
Patent 12544379*PED expires
Listed listed patent expiration.
Feb 07, 2035
in 8 yr 9 mo
Patent 12544380*PED expires
Listed listed patent expiration.
Feb 07, 2035
in 8 yr 9 mo
Patent 10799506 expires
Listed drug product patent expiration.
Apr 14, 2036
in 10 yr
Patent 12064434 expires
Listed drug product patent expiration.
Apr 14, 2036
in 10 yr
Patent 12419894 expires
Listed drug product patent expiration.
Apr 14, 2036
in 10 yr
Patent 10799506*PED expires
Listed listed patent expiration.
Oct 14, 2036
in 10 yr 6 mo
Patent 12064434*PED expires
Listed listed patent expiration.
Oct 14, 2036
in 10 yr 6 mo
Patent 12419894*PED expires
Listed listed patent expiration.
Oct 14, 2036
in 10 yr 6 mo
Pharmaceutical detail
Active ingredient
RIBOCICLIB SUCCINATE
Strength
EQ 200MG BASE
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 209092
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Marketing exclusivity (2)
- I-950New indication exclusivity (3 years)
Sep 17, 2027
in 1 yr 3 mo
- PEDPediatric exclusivity (adds 6 months)
Mar 17, 2028
in 1 yr 9 mo
Listed patents (43)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8324225 | Jun 17, 2028 | in 2 yr | SubstanceProduct |
| 8324225*PED | Dec 17, 2028 | in 2 yr 6 mo | |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-2355 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-2356 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-1981 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-3999 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-3266 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-3265 |
| 9416136 | Aug 20, 2029 | in 3 yr 3 mo | U-3975 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-1981 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-2356 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-2355 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-3999 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-3265 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-3266 |
| 8962630 | Dec 09, 2029 | in 3 yr 6 mo | U-3975 |
| 9416136*PED | Feb 20, 2030 | in 3 yr 9 mo | |
| 8685980 | May 25, 2030 | in 4 yr | SubstanceProduct |
| 8962630*PED | Jun 09, 2030 | in 4 yr | |
| 8685980*PED | Nov 25, 2030 | in 4 yr 6 mo | |
| 8415355 | Mar 13, 2031 | in 4 yr 10 mo | SubstanceProduct |
| 8415355*PED | Sep 13, 2031 | in 5 yr 4 mo | |
| 9193732 | Nov 09, 2031 | in 5 yr 6 mo | SubstanceProduct |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-2355 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-2356 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-3999 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-1981 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-3975 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-3265 |
| 9868739 | Nov 09, 2031 | in 5 yr 6 mo | U-3266 |
| 9193732*PED | May 09, 2032 | in 6 yr | |
| 9868739*PED | May 09, 2032 | in 6 yr | |
| 12544379 | Aug 07, 2034 | in 8 yr 3 mo | U-3975 |
| 12544380 | Aug 07, 2034 | in 8 yr 3 mo | U-4404 |
| 12544380 | Aug 07, 2034 | in 8 yr 3 mo | U-4405 |
| 12544379*PED | Feb 07, 2035 | in 8 yr 9 mo | |
| 12544380*PED | Feb 07, 2035 | in 8 yr 9 mo | |
| 10799506 | Apr 14, 2036 | in 10 yr | Product |
| 12064434 | Apr 14, 2036 | in 10 yr | Product |
| 12419894 | Apr 14, 2036 | in 10 yr | Product |
| 10799506*PED | Oct 14, 2036 | in 10 yr 6 mo | |
| 12064434*PED | Oct 14, 2036 | in 10 yr 6 mo | |
| 12419894*PED | Oct 14, 2036 | in 10 yr 6 mo |

